Overview

The Efficacy and Safety of Retreatment With HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study

Status:
Completed

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE. This study was to compare HAIC with FOLFOX with sorafenib who showed TACE-resistant.

Phase:

N/A

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Sorafenib